biote Corp.
BTMD evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for BTMD—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BTMD
biote Corp. (BTMD) is a company that provides a practice-building platform for hormone optimization and related therapies, primarily serving a network of certified practitioners in the U.S. and select international markets.
Key risk: Revenue decline trend
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 1 clinical trial for biote Corp..
biote Corp. (BTMD) is a company that provides a practice-building platform for hormone optimization and related therapies, primarily serving a network of certified practitioners in the U.S. and select international markets.
- Total revenue was $44.2 million for the three months ended June 30, 2026, compared to $48.9 million for the same period in 2025 [sec_mda · as of 2026-08-07].
- Net loss was $7.4 million for the three months ended June 30, 2026, versus net income of $3.9 million in the prior-year period [sec_mda · as of 2026-08-07].
- Cash and equivalents stood at $11.2 million as of June 30, 2026 [sec].
- Shareholders' equity was negative $58.5 million as of June 30, 2026, with total debt of $128.1 million [sec].
- The company has a Second Amendment and 2027 Commitment in place and believes it is well positioned to meet product demands and expand its Biote-certified clinic network [sec_mda · as of 2026-08-07].
What works
- The company has a Second Amendment and 2027 Commitment in place, supporting its ability to meet product demands and expand its certified clinic network [sec_mda · as of 2026-08-07].
- biote has existing direct manufacturing capabilities that management believes position it well for continued growth [sec_mda · as of 2026-08-07].
- The company has a published nine-year retrospective breast cancer study in the European Journal of Breast Health, supporting its clinical research program [sec_mda · as of 2026-03-13].
What to weigh
- Revenue declined from $48.9 million to $44.2 million for the three months ended June 30, 2026 compared to the prior year [sec_mda · as of 2026-08-07].
- The company reported a net loss of $7.4 million for the three months ended June 30, 2026, compared to net income of $3.9 million in the same period of 2025 [sec_mda · as of 2026-08-07].
- Shareholders' equity is negative $58.5 million as of June 30, 2026, with total debt of $128.1 million [sec].
- The company faces risks related to accessing additional capital, and a recession or market corrections could materially affect its business [sec_mda · as of 2026-08-07].
From the filings
Quoted directly from source documents.
Second Amendment and 2027 Commitment
“Second Amendment and 2027 Commitment in place and through our existing direct manufacturing capabilities, we believe we are well positioned to continue meeting the product demands of our current Biote certified practitioners while focusing on expanding our Biote-certified clinic network.”
SEC MD&A · August 7, 2026
Clinical research publication
“In 2021, we published a nine-year retrospective breast cancer study in the European Journal of Breast Health.”
SEC MD&A · March 13, 2026
Risks & what to watch (4)›
Key risks
- Revenue decline trend — Total revenue decreased from $48.9M to $44.2M in Q2 2026 year-over-year [sec_mda · as of 2026-08-07].
- Negative shareholders' equity — Shareholders' equity is negative $58.5M as of June 30, 2026, indicating accumulated losses exceed equity [sec].
- High debt burden — Total debt of $128.1M as of June 30, 2026, with limited cash of $11.2M [sec].
- Capital access risk — Inability to raise capital could force delay or reduction of R&D and other efforts [sec_mda · as of 2026-08-07].
What to watch
- Revenue trends in upcoming quarters, given the year-over-year decline in Q2 2026 [sec_mda · as of 2026-08-07].
- Progress on expanding the Biote-certified clinic network, a key growth strategy [sec_mda · as of 2026-08-07].
- Ability to manage debt and improve shareholders' equity, given negative equity and high leverage [sec].
- Impact of global trade policies and economic conditions on the business [sec_mda · as of 2026-08-07].
Sources: Catalysts · SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run biote Corp. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available biote Corp. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
52.9 months
OCF -$1M · Net income -$7M
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
2 buys · 0 sells (180d)
Runway
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
83
Total value held
$18.3M
| Holder | Shares | Value |
|---|---|---|
| 325 capital llc | 4,548,127 | $6.1M |
| vanguard capital management llc | 2,227,710 | $3.0M |
| blackrock, inc. | 1,739,244 | $2.3M |
| state street corp | 646,954 | $873K |
| geode capital management, llc | 615,662 | $831K |
| dimensional fund advisors lp | 543,494 | $734K |
| globeflex capital l p | 272,400 | $368K |
| northern trust corp | 269,113 | $363K |
| renaissance technologies llc | 265,916 | $359K |
| rice hall james & associates, llc | 250,019 | $338K |
Showing top 10 of 83 institutional holders of biote Corp.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 6.3%
- Days to cover
- 5.6
- Shares short
- 1,482,207
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
BTMD short interestGovernance
Frequently asked questions
What is the AI investment thesis for biote Corp.?
biote Corp. (BTMD) is a company that provides a practice-building platform for hormone optimization and related therapies, primarily serving a network of certified practitioners in the U.S. and select international markets.
Who is the CEO of biote Corp.?
Mr. Robert C. Peterson is the chief executive officer of biote Corp. (BTMD).
Where is biote Corp. headquartered?
biote Corp. (BTMD) is headquartered in Irving, TX, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.